Startup · $8m raised
Sydney, NSW
Every investor coverage indicates participated in a round NEXSEN BioTech raised.
The transaction that ended NEXSEN BioTech's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 14 Oct 2025 | - | Mirage News, proactiveinvestors.com, newshub.medianet.com.au |
Companies NEXSEN BioTech acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Vipul Bansal | Chief Innovation Officer | Mirage News, newshub.medianet.com.au |
| Reece O'Connell | Executive Chairman | Mirage News, proactiveinvestors.com, newshub.medianet.com.au |
Stories naming NEXSEN BioTech. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian nanobiotech firm Nexsen has begun trading on the sharemarket after an $8m IPO; earlier government grants and an RMIT research collaboration are also noted.
Nexsen, a biotech developing rapid pregnancy diagnostics for GBS, has kicked off an IPO aiming for ASX listing by end of September; Regal is named as an earlier backer.
Federal grants roundup: 21 Cooperative Research Centres Projects awards worth $51 million in Round 15, with EQ Plastics, Optiscan Imaging and NEXSEN BioTech each receiving $3 million for product development.
Also RenewEconomy
Nexsen's investor page invites applications for its IPO under an August 2025 prospectus lodged with the corporate regulator; the share sale has not completed, so no funding is recorded.